The safety profiles of several commonly used advanced therapies for Crohn’s disease appear similar, with no significant differences observed in risks for serious infections and cardiovascular adverse ...
Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...
Nicotine e-cigarettes have been found to be more effective than traditional methods in helping adults quit smoking, with quit ...
Information from CMS’s published explanations of the Medicare Drug Price Negotiation Program negotiated prices for 2027 will ...
A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of ...
Sujay Jadhav, CEO of Verana Health highlights how real-time real-world data dashboards are transforming the way life sciences ...
It's not a one-size-fits-all drug.
Advances in Bladder Cancer: innovation in diagnostics, therapeutic technology, and clinical pathways
Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...
Validated provider-side feedback ranks InteliChart first overall among independent, EHR-agnostic patient engagement platforms for the fourth consecutive year, as healthcare organizations intensify ...
Stopping popular weight-loss injections like Ozempic or Mounjaro might not trigger the dramatic rebound many fear. A large real-world study of nearly 8,000 patients found that most people who ...
Three presentations at ACC reinforce Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes and results in ...
Tirzepatide is linked to lower cardiovascular risk than dulaglutide for adults with type 2 diabetes and atherosclerotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results